Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology
SINGAPORE, Sept. 25, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has announced that its licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).
Expanding Patent Portfolio
CytoMed is thrilled to strengthen its existing suite of patents with the grant of a patent for its iPSC-based technology in China. This novel technology has also been granted a patent in Japan, where the iPSC technology was pioneered in 2006. With these patents, the company’s current patent portfolio now spans three countries, including the US and China.
Potential Breakthrough in Cancer Treatment
CytoMed’s iPSC-based technology allows for the generation of γδ NKT cells, a novel type of synthetic hybrid immune cells. These cells express cancer recognition receptors of both γδ T cells and natural killer (NK) cells, enabling them to recognize a wide range of cancers without genetic modification or the use of viral vectors. As an allogeneic cell source, these iPSC-derived γδ NKT cells have the potential to become an “off-the-shelf” cell therapy applicable to a large pool of patients.
Promising Preclinical Development
The recently granted patent titled “Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells” covers the technologies to derive synthetic γδ NKT cells for the treatment of various types of cancers, including hematological malignancies and solid tumors. This asset is currently under preclinical development, bringing hope for improved cancer treatment options in the future.
For more information about CytoMed Therapeutics Limited and their innovative cell-based immunotherapies, please visit www.cytomed.sg.
